Ivax Glucophage XR Launch Halted By Purepac Exclusivity Suit
Executive Summary
Purepac's lawsuit over FDA's 180-day exclusivity determination on generic metformin extended-release challenges the agency's interpretation of first-to-file rights for amended ANDAs
You may also be interested in...
Glucophage XR Settlement: Purepac, Ivax Split Generic Profits For 180 Days
Ivax and Purepac's exclusivity rights settlement for a generic version of Glucophage XR means FDA has avoided a legal challenge to its interpretation of first-to-file requirements for new ANDAs compared to amended applications
Glucophage XR Settlement: Purepac, Ivax Split Generic Profits For 180 Days
Ivax and Purepac's exclusivity rights settlement for a generic version of Glucophage XR means FDA has avoided a legal challenge to its interpretation of first-to-file requirements for new ANDAs compared to amended applications
Ivax Glucophage XR Generic Exclusivity Rights Questioned By Judge
FDA's rationale for awarding Glucophage XR generic marketing exclusivity to Ivax rather than Purepac received a skeptical hearing from a federal judge Nov. 12